| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | Development of an Extracellular Vesicle-Based In Vivo Macrophage Reprogramming Therapy for Inflammatory Bowel Disease with Enhanced Targeted Delivery Efficiency of NLRP3 ASO | ||||||
| Gene & Nucleic acids | IBD(Ulcerative colitis) | NLRP3, CD47 | Hit | SHIFTBIO.INC | RS-2025-02122993 | ||